### Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

#### DUSA PHARMACEUTICALS INC

Form 3

March 14, 2006

## FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0104

**OMB APPROVAL** 

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Number: Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

**SECURITIES** 

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement DUSA PHARMACEUTICALS INC [DUSA] À Penneys Neal Stuart (Month/Day/Year) 03/10/2006 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 1825 S.E. 7TH STREET (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) 10% Owner \_X\_ Director \_X\_ Form filed by One Reporting Officer \_Other Person (give title below) (specify below) FT. Form filed by More than One LAUDERDALE, Â FLÂ 33316 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) D Â Common Stock, no par value per share 10,663 (1) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 $Table\ II\ -\ Derivative\ Securities\ Beneficially\ Owned\ (\textit{e.g.},\ puts,\ calls,\ warrants,\ options,\ convertible\ securities)$ 

(Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Securities Underlying Derivative Security		Conversion or Exercise	Ownership Form of	(Instr. 5)
			(Instr. 4)		Price of	Derivative	
		Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D) or Indirect	

Shares

(I) (Instr. 5)

### **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Penneys Neal Stuart

1825 S.E. 7TH STREET

X Â Â

FT. LAUDERDALE, Â FLÂ 33316

### **Signatures**

/s/ Neal S.

03/14/2006

Penneys

Date

\*\*Signature of Reporting Person

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Such shares are held jointly and were acquired by Dr. Penneys in connection with the merger of DUSA Pharmaceuticals, Inc. and Sirius Laboratories, Inc. (the "Merger"). Pursuant to the Merger, Dr. Penneys received such 10,663 shares of DUSA common stock and a cash payment in exchange for 101.791 shares of Sirius common stock so held by Dr. Penneys prior to the Merger. Of such 10,663 shares of

(1) payment in exchange for 101,791 shares of Sirius common stock so held by Dr. Penneys prior to the Merger. Of such 10,663 shares of DUSA common stock, 1,881 shares are being held in escrow for up to two years subject to certain indemnification provisions of the merger agreement. Upon closing of the Merger, Dr. Penneys became a member of the Board of Directors of DUSA.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2